• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.

    As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Stockholders Meeting in January 2024. With the addition of Chattopadhyay, Ashland temporarily increases the size of the Board to 11 members until the next Annual Stockholders Meeting in January 2024.

    Chattopadhyay is a broadly experienced global executive who brings strong industry leadership in manufacturing, distribution, supply chain, and more. He has led complex operations that span 22 countries including cutting-edge manufacturing technology while successfully navigating the ever-changing, globally complex, and heavily regulated industry of biopharmaceuticals.

    "I am pleased to welcome Sanat as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy and increase our focus and scale in pharmaceuticals, personal care and coatings, I am confident Sanat will provide important perspectives for our team. And once again, I want to thank Jay and Brendan for their dedicated service to the Board."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    Seth A. MrozekCarolmarie C. Brown
    +1 (302) 594-5010+1 (302) 995-3158
    [email protected][email protected]

    Attachment

    • Ashland_announces_new_board_member_20231114


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Ashland Inc.
    $ASH
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Ashland Inc.
    $ASH
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    Ashland Inc.
    $ASH
    3/5/2025Buy → Neutral
    Seaport Research Partners
    Merck & Company Inc.
    $MRK
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    Merck & Company Inc.
    $MRK
    1/8/2025$110.00Buy → Hold
    Truist
    More analyst ratings

    $ASH
    $MRK
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Ashland Inc.

    SCHEDULE 13G - ASHLAND INC. (0001674862) (Subject)

    8/14/25 10:48:33 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 13F-HR filed by Merck & Company Inc.

    13F-HR - Merck & Co., Inc. (0000310158) (Filer)

    8/13/25 5:05:55 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Merck & Company Inc.

    10-Q - Merck & Co., Inc. (0000310158) (Filer)

    8/5/25 4:13:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Info&Digital Officer Williams David Michael exercised 17,119 shares at a strike of $79.29 and covered exercise/tax liability with 8,432 shares, increasing direct ownership by 36% to 33,013 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    8/5/25 8:46:15 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer Guindo Chirfi exercised 36,903 shares at a strike of $79.29 and covered exercise/tax liability with 18,175 shares, increasing direct ownership by 27% to 89,234 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    8/5/25 8:43:24 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and GM, Life Sciences Assis Alessandra Faccin exercised 3,123 shares at a strike of $51.26 and covered exercise/tax liability with 1,327 shares, increasing direct ownership by 57% to 4,946 units (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    7/28/25 4:30:42 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Merck downgraded by Citigroup with a new price target

    Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

    5/14/25 8:57:17 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland downgraded by Wells Fargo

    Wells Fargo downgraded Ashland from Overweight to Equal Weight

    5/1/25 3:02:01 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Cantor Fitzgerald initiated coverage on Merck with a new price target

    Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

    4/22/25 8:01:38 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

    Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer First Breakthrough Therapy Designation for Daiichi Sankyo and Merck's ifinatamab deruxtecan based on IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial Fourteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Ifinatamab derux

    8/18/25 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

    Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.

    8/13/25 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

    First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in this cisplatin-ineligible patient population, representing significant advancement in MIBC Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectom

    8/12/25 5:33:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ashland announces executive leadership changes

    WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

    5/5/25 5:00:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ASH
    $MRK
    Financials

    Live finance-specific insights

    View All

    Ashland board authorizes quarterly dividend

    WILMINGTON, Del., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock. The dividend will be payable on September 15, 2025, to stockholders of record at the close of business on September 1, 2025. As of July 31, 2025, there were 45,709,431 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural

    8/8/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland reports third quarter fiscal 2025 results and narrows full-year outlook range

    Sales of $463 million, down 15 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $53 million or 10 percent versus the prior-year quarter. Excluding these initiatives, sales declined five percentLoss from continuing operations of $719 million, or $(15.70) per diluted share, primarily reflecting a non-cash goodwill impairment charge of $706 millionAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $48 million, or $1.04 per diluted shareNet loss of $742 million, or

    7/29/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

    Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange WINREVAIR Sales Were $336 Million Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and Excluding the Impact of Foreign Exchange GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both Nominally and Excluding the Impact of Foreign Exchange GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement Announce

    7/29/25 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary